Clinical Trials Logo

DiGeorge Syndrome clinical trials

View clinical trials related to DiGeorge Syndrome.

Filter by:

NCT ID: NCT00768820 Recruiting - Fragile X Syndrome Clinical Trials

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

VCFS
Start date: May 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

NCT ID: NCT00556530 Recruiting - DiGeorge Syndrome Clinical Trials

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

Start date: July 2016
Phase:
Study type: Observational

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

NCT ID: NCT00161109 Recruiting - Clinical trials for Chromosome 22q11.2 Deletion Syndrome

Genetics and Psychopathology in the 22q11 Deletion Syndrome

Start date: October 2002
Phase: N/A
Study type: Observational

The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms.

NCT ID: NCT00005102 Recruiting - DiGeorge Syndrome Clinical Trials

Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

Start date: January 1995
Phase: N/A
Study type: Observational

OBJECTIVES: I. Determine the pattern of immunologic reconstitution in patients with T-cell compromise due to DiGeorge syndrome or velocardiofacial syndrome. II. Determine any correlation between immunologic function in these patients and chromosome 22 deletion breakpoints. III. Determine presence of sustained immunologic compromise in older patients.